Ranajit Mandal

Ranajit Mandal

Auto-generated profile, based on publicly available information

Ranajit Mandal

Department of Gynecology Oncology, The Gujrat Cancer and Research Institute, Ahmedabad, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Journal of the Electrochemical Society
Verified
Journal Article
Closed access
PDF file
HKHiranmoy Kotal
Hiranmoy Kotal
TKThangapandi Kalyani
Thangapandi Kalyani
ASArumugam Sangili
Arumugam Sangili
RMRanajit Kumar Mandal
Ranajit Kumar Mandal
SGSuvankar Ghorai
Suvankar Ghorai
SJSaikat Kumar Jana
Saikat Kumar Jana
Cervical cancer (CC), a significant contributor to the mortality of females globally, manifests an annual incidence of 500,000 cases and is predominantly linked to the human papillomavirus (HPV) infection. The pressing demand for affordable and user-friendly assays for CC detection is highlighted by the limited availability and dependability of diagnostic screening tools, especially in developing countries. In response to the critical need for enhanced cervical cancer diagnostics, we present an innovative electrochemical immunosensor designed for the selective detection of the HPV 16-E7 oncoprotein. The immunosensing platform is constructed from a gold-graphitic carbon nitride (Au-g-C3N4) nanocomposite, with antibodies immobilized through a physical adsorption process onto the sensing platform. Employing Square Wave Voltammetry (SWV), we systematically evaluated the antigen-antibody interaction, achieving ultrasensitive detection of E7 with ferric/ferrocyanide. The linear detection range of the proposed sensor for E7 antigen is 0.01 fg ml−1 to 1 ng ml−1, assuming ideal conditions and an impressive Limit of Detection (LOD) of 0.0065 fg ml−1. The accuracy of the proposed immunosensor was effectively evaluated in contrast to Enzyme linked immunosorbent assay (ELISA). Finally, the proposed immunosensor exhibited favourable selectivity, sensitivity, and reproducibility upon introduction to clinical samples, thereby validating its potential suitability for point-of-care testing aimed at the timely detection of CC.

11 June 2018 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
KTKatayoun Taghavi
Katayoun Taghavi
DBDipanwita Banerjee
Dipanwita Banerjee
RMRanajit Mandal
Ranajit Mandal
HKHelena Kopp Kallner
Helena Kopp Kallner
MTMalin Thorsell
Malin Thorsell
EWElisabeth Wikström
Elisabeth Wikström
This cross-sectional pilot study evaluates diagnostic accuracy of live colposcopy versus static image Swede-score evaluation for detecting significant precancerous cervical lesions greater than, or equal to grade 2 severity (CIN2+). VIA or HrHPV positive women were examined using a mobile colposcope, in a rural clinic in Kolkata, India. Live versus static Swede-score colposcopy assessments were made independently. All assessments were by gynecologists, junior or expert. Static image assessors were blinded to live scoring, patient information and final histopathology result. Primary outcome was the ability to detect CIN2+ lesions verified by directed biopsies. Diagnostic accuracy was calculated for live versus static Swede-score in detecting CIN2+ lesions, as well as for interclass correlation. 495 images from 94 VIA positive women were evaluated in this study. Thirteen women (13.9%) had CIN2+ on biopsy. No significant difference was found in the detection of CIN2+ lesions between live and static assessors (area under curve = 0.69 versus 0.71, p = 0.63). A Swede-score of 4+, had a sensitivity of 76.9% (95% CI 46.2–95.0%) and 84.6% (95% CI 54.6–98.1%), for live- and static-image assessment respectively. The corresponding positive predictive values were found to be 90.9% (95% CI 75.7–98.1%) and 92.6% (95% CI 75.7–99.1%). The interclass correlation was good (kappa statistic = 0.60) for the senior static assessors. Swede-score evaluation of static colposcopy images was found to reliably detect CIN2+ lesions in this study. Larger studies are needed to further develop the colposcopy telemedicine concept which may offer reliable guidance in management where direct specialist input is not available. Ethical approval of the study was obtained by the Chittaranjan National Cancer Institute (CNCI) Human Research Ethics Committee (4.311/27/2014). The trial was retrospectively registered in the Clinical Trails Registry of India CTRI/2018/03/012470 .

29 October 2024 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
KGKrishnendu Gupta
Krishnendu Gupta
RMRanajit Mandal
Ranajit Mandal
PCPuja Chatterjee
Puja Chatterjee

27 November 2023 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
PDPriyanka Dutta
Priyanka Dutta
DPDebolina Pal
Debolina Pal
FSFarhin Sultana
Farhin Sultana
RMRanajit Kumar Mandal
Ranajit Kumar Mandal
ARAnup Roy
Anup Roy
CPChinmay Kumar Panda
Chinmay Kumar Panda

26 April 2023 in International Journal of Clinical Trials
Verified
Journal Article
Open access
PDF file
SBSreeya Bose
Sreeya Bose
PBPartha Basu
Partha Basu
SSSankar Sengupta
Sankar Sengupta
RMRanajit Mandal
Ranajit Mandal
Background: A system comprising of screening for pre-cancerous lesions succeeded by therapeutic interventions can greatly reduce the incidence of cervical cancer. High risk HPV detection in urine has proven itself as a potential primary screening tool. However, only a few studies have showed it’s concordance with matched self-collected vaginal samples while screening for high risk HPV infection in the community. Objective of the study was to determine the concordance between first void urine sample and self-collected vaginal sample for high risk HPV detection using Cobas 4800. The sensitivity and positive predictive value of screening by urine HPV testing for CIN 2+ detection would also be done along with its acceptability and cost analysis in community screening. Methods: This study will include women between 30-60 years with intact cervix and no precancerous lesions. Self-sampling will be provided by participants in the form of urine and vaginal swab collection by the Collipee device and vaginal swab stick respectively. This will be followed by high risk HPV testing using Cobas 4800 technology. The participants will also be asked to fill up a questionnaire about the acceptability of urine sampling for cancer screening. Conclusions: Screening tools can perhaps be diversified in order to suit the needs of low and middle income countries. Research and development of cervical cancer screening tools could hence bring to light feasible alternatives that could further improve compliance of non-attenders. Trial registration: The trial is registered with clinical trials registry (CTRI/2023/01/049322).

6 December 2025 in The Journal of Obstetrics and Gynecology of India
Verified
Journal Article
Closed access
PDF file
MNMegha Nandwani
Megha Nandwani
RMRanajit Mandal
Ranajit Mandal
MVManisha Vernekar
Manisha Vernekar
BKBijoy Kar
Bijoy Kar
DBDipanwita Banerjee
Dipanwita Banerjee
JCJayanta Chakrabarti
Jayanta Chakrabarti